Page 13 - Pharma Sector

Unichem gets USFDA approval for high blood pressure drug Chlorthalidone

Unichem said the product will be commercialised from its Ghaziabad plant

At 13%, domestic pharma sales witness double-digit growth in July

Volume growth in the domestic market had turned negative in the last two months but was a big growth driver in July

Aurobindo Pharma gains nearly 8% on growth prospects in US market

The completion of Sandoz acquisition and new product launches are triggers

Aurobindo Q1 profit up 39.5% at Rs 636 crore on strong revenue growth

Revenue from operations rose 28.1% year-on-year to Rs 5,444.6 crore during the quarter under review

Fund managers bet on pharma sector as pricing pressure in US is stabilising

The Indian pharma sector has many attractive opportunities before it, such as the growing adoption of generic drugs in developed markets

Lupin gets Establishment Inspection Report from FDA for Aurangabad facility

The facility was inspected by the US Food and Drug Administration

Active pharmaceutical ingredients focus helps drug firms offset slowdown

Besides captive consumption, the company also supplies APIs to external customers across international markets

Nilesh Gupta to Dilip Shanghvi, most pharma CEOs took a pay cut in FY19

The CEOs' salaries also have taken a brunt. A quick analysis shows that Shanghvi took a whopping 99 per cent pay cut

As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

India Inc's expenditure on R&D declines to lowest level in six years

Lower expenditure by pharmaceutical companies may be a key reason for the fall

Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain

Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers

Dr Reddy's Labs looks to recover from Q1 blues with multiple growth drivers

Steady improvement in the US and India market growth keeps analysts positive

No plans to re-enter domestic formulations in current fiscal: Piramal V-C

Last year, Ajay Piramal, chairman of Piramal Enterprises, had indicated that the firm was exploring a possible re-entry into the domestic formulations market

Purity norms drive nanotech in pharma

A big challenge that drug makers face is the high volume of chemicals which are used and then wasted during the manufacturing process

Caplin Labs gets USFDA nod for injection to prevent excessive blood loss

Caplin Steriles said it has developed and filed 11 ANDAs on its own and with partners, with 5 approvals so far

Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright

The JV will set up a manufacturing facility of respiratory products; the plant is expected to be commissioned in 2020

Sun Pharma bets on nurturing specialty portfolio outlook; stock rises 3.6%

Street is bullish on stabilising US generics sales, upsides from niche portfolio, and inexpensive valuations

Indian pharma firms compliance with USFDA norms improving of late

Pharma industry feels it is unfairly targeted in Katherine Eban's recent book 'Bottle of Lies'

Q4 results preview: Growth recovery for pharma after a muted first half

Lupin and Dr Reddy's lead in terms of growth, Sun Pharma may be impacted by write backs

Combination drug market declines 56% in March as govt clamps down

Govt has banned over 340 FDCs and over 900 are under scrutiny